The Swiss medicines agency, Swissmedic, and the national association of research ethics committees have issued a position paper on decentralized trials (DCTs) to address the various questions and considerations that have arisen so far on the topic, which continues to draw the interest of all stakeholders involved in clinical research.
The COVID-19 pandemic has drawn a lot of attention to DCTs because of their ability to support research through technology, but this also poses new challenges in terms of ensuring compliance. In DCTs, digital recording and/or transmission of data in the context of trial-related interventions plays a significant role
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?